<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01205685</url>
  </required_header>
  <id_info>
    <org_study_id>VICC BRE 09112</org_study_id>
    <nct_id>NCT01205685</nct_id>
  </id_info>
  <brief_title>Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-Sensitive Metastatic Breast Cancer</brief_title>
  <official_title>A Phase II Trial of Endocrine Therapy in Combination With OSI-906 (an IGF-1R Inhibitor) and Erlotinib (Tarceva®, an EGFR Inhibitor) in Patients With Hormone-sensitive Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt-Ingram Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt-Ingram Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Erlotinib attacks a part of cancer cells that helps them live and grow. Studies done in human
      beings show that this drug can make a difference in the way anti-estrogens work in
      hormone-sensitive breast cancers. OSI-906 attacks a different part of the cancer cell that
      helps them live and grow. Studies done in the laboratory show that OSI-906 can make a
      difference in the way anti-estrogens work in hormone-sensitive breast cancers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The safety run component of this trial is to determine the safety profile of the OSI-906,
      erlotinib and anti-endocrine treatment combination. The phase II component evaluates the
      antitumor activity of the combination OSI-906, erlotinib and endocrine therapy.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    PI closed study early, all patients experienced severe toxicities and progressed
  </why_stopped>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Anti-tumor Activity of OSI-906</measure>
    <time_frame>From study entry to 6 months</time_frame>
    <description>Time to progression measured in months from study entry to date of disease progression</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety Profile Based on Number of Patients With Each Worst-grade Toxicity</measure>
    <time_frame>Every 4 weeks up to 24 weeks</time_frame>
    <description>According to National Cancer Institute Common Toxicity Criteria for Adverse Events with 1 = mild, 2 = moderate, 3 = severe, 4 = life threatening/disabling, and 5 = death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Tumor Response Per RECIST</measure>
    <time_frame>Every 12 weeks to tumor progression</time_frame>
    <description>Per RECIST criteria v. 1.1: measurable lesions: complete response (CR) disappearance of target lesions, partial response (PR) &gt; 30% decrease in the sum of the longest diameter (LD) of target lesions, progressive disease (PD) &gt; 20% increase in the sum of the LD of target lesions or appearance of new lesions, stable disease (SD) neither sufficient decrease nor increase of the sum of smallest sum of the LD of target lesions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlative Studies</measure>
    <time_frame>&lt; or = to 2 weeks before initiation of Phase II study treatment period</time_frame>
    <description>Biomarkers associated with response to OSI-906 + Erlotinib + Letrozole + Goserelin</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Hormone-sensitive Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>OSI-906 + Erlotinib + Letrozole + Goserelin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OSI-906 in a pill form, by mouth, twice a day (12 hours a part)
Erlotinib in a pill form, by mouth, once a day
Letrozole in a pill form, by mouth, once a day
Goserelin, by injection once per month for women who are pre-menopausal</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OSI-906</intervention_name>
    <description>In a pill form by mouth, twice a day (12 hours apart)
During the safety run portion of the study&quot;
Dose level 2 = 150 mg twice a day
Dose level 1 = 100 mg twice a day
Dose level -1 = 100 mg twice a day
Dose level -2 = 100 mg twice a day</description>
    <arm_group_label>OSI-906 + Erlotinib + Letrozole + Goserelin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib</intervention_name>
    <description>During the safety run phase of the study:
Dose Level 2 = 100 mg/d
Dose Level 1 = 100 mg/d
Dose Level -1= 75 mg/d
Dose Level -2 = 50 mg/d</description>
    <arm_group_label>OSI-906 + Erlotinib + Letrozole + Goserelin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole</intervention_name>
    <description>In a pill form, by mouth, once per day at 2.5 mg/d.</description>
    <arm_group_label>OSI-906 + Erlotinib + Letrozole + Goserelin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Goserelin</intervention_name>
    <description>For pre-menopausal patients only. Given as an injection once a month at 3.6 mg/month.</description>
    <arm_group_label>OSI-906 + Erlotinib + Letrozole + Goserelin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must provide informed written consent.

          -  Patients must be ≥18 years of age.

          -  ECOG performance status 0-1.

          -  Patients with clinical stage IV invasive mammary carcinoma, previously documented by
             histological analysis, which is ER-positive and/or PR-positive by immunohistochemistry
             (IHC), which had previous endocrine therapy in the metastatic setting or had
             metastatic recurrence within 6 months of adjuvant endocrine therapy. Patients may have
             either measurable or non-measurable disease, both are allowed.

          -  Patients whose breast cancers are also HER2-overexpressed (IHC 3+ or FISHpositive)
             need to have had previous treatment exposure to trastuzumab (Herceptin®)

          -  Life expectancy ≥ 6 months

          -  Patients must have adequate hematologic, hepatic, and renal function. All tests must
             be obtained less than 2 weeks from study entry. This includes:

               -  ANC ≥1250/mm3

               -  Platelet count ≥100,000/mm3

               -  Creatinine ≤1.5X upper limits of normal

               -  Bilirubin, SGOT, SGPT ≤ 1.5 X upper limits of normal if no liver metastasis
                  present*

               -  Bilirubin, SGOT, SGPT, alkaline phosphatase ≤ 3 X upper limits of normal if liver
                  metastasis present* *for patients with Gilbert's syndrome, direct bilirubin will
                  be measured instead of total bilirubin

          -  Able to swallow and retain oral medication.

          -  Pre-menopausal patients must have a negative pregnancy test prior to participating in
             the study. Women of childbearing age and their male counter parts should use a barrier
             method of contraception during and for 3 months following protocol therapy.

          -  Post-menopausal female subjects should be defined prior to protocol enrollment by any
             of the following:

               -  Subjects at least 55 years of age;

               -  Subjects under 55 years of age and amenorrheic for at least 12 months or
                  follicle-stimulating hormone (FSH) values ≥40 IU/L and estradiol levels

                  ≤20 IU/L;

               -  Prior bilateral oophorectomy or prior radiation castration with amenorrhea for at
                  least 6 months.

          -  Patients may receive concurrent radiation therapy to painful bone metastases or areas
             of impending bone fracture as long as radiation therapy is initiated prior to study
             entry. Patients who have received prior radiotherapy must have recovered from any
             toxicity induced by this treatment (toxicity grade ≤ 1).

          -  Patients must be disease-free of prior invasive cancers for &gt; 5 years with the
             exception of basal or squamous cancer of the skin or cervical carcinoma in situ.

          -  Subjects must complete all screening assessments as outlined in the protocol.

          -  Patients must have available tissue (archived formalin-fixed paraffin embedded blocks
             (FFPB) or fresh frozen tissue from original diagnosis or metastatic setting)for
             correlative studies. Tissue needs to be sent to VUMC (see Appendix E) at the time of
             registration. Patients will not be able to start study drugs without tissue
             availability.

        Exclusion Criteria:

          -  Locally recurrent resectable breast cancer.

          -  Pregnant or lactating women.

          -  Patients must not have had &gt; than 4 prior chemotherapy treatments in the metastatic
             setting. This restriction does not include endocrine therapies or single agent
             biologic therapies.

          -  Use of CYP3A4 and CYP1A2 modifiers or drugs that prolong QTcF with high risk for
             Torsade de Pointes (see Appendix A)

          -  Any kind of malabsorption syndrome significantly affecting gastrointestinal function.

          -  History of other malignancy within 5 years prior to enrollment. Subjects with a
             history of completely resected non-melanoma skin cancer or successfully treated in
             situ carcinomas are eligible.

          -  Patients with baseline QTcF&gt; 450 msec

          -  Patients with diabetes, glucose &gt; 160 mg/dL or receiving ongoing antihyperglycemic
             therapies

          -  Uncontrolled intercurrent illness including, but not limited to:

               -  ongoing or active infection requiring parenteral antibiotics

               -  impairment of lung function (COPD &gt; grade 2, lung conditions requiring oxygen
                  therapy)

               -  symptomatic congestive heart failure (class III or IV of the New York Heart
                  Association classification for heart disease)

               -  unstable angina pectoris, angioplasty, stenting, or myocardial infarction within
                  6 months

               -  uncontrolled hypertension (systolic blood pressure &gt;180 mm Hg or diastolic blood
                  pressure &gt;100 mm Hg, found on two consecutive measurements separated by a 1-week
                  period despite adequate medical support)

               -  clinically significant cardiac arrhythmia (multifocal premature ventricular
                  contractions, bigeminy, trigeminy, ventricular tachycardia that is symptomatic or
                  requires treatment [National Cancer Institute -Common Terminology Criteria for
                  Adverse Events, Version 4.0, grade 3]

               -  psychiatric illness/social situations that would compromise patient safety or
                  limit compliance with study requirements including maintenance of a
                  compliance/pill diary

          -  Patients with symptomatic brain metastases (patients with a history of brain
             metastases must be clinically stable for more than 3 weeks from completion of
             radiation treatment and not taking steroids or therapeutic anticonvulsants that are
             CYP3A4 modifiers)

          -  Patients with asymptomatic brain metastasis on prophylactic anticonvulsants that are
             CYP3A4 modifiers

          -  Concurrent anti-cancer therapy (chemotherapy, radiation therapy, surgery,
             immunotherapy, hormonal therapy, biologic therapy) other than the ones specified in
             the protocol. Patients must have discontinued the above cancer therapies for 1 week
             prior to the first dose of study medication, as well as recovered from toxicity (to ≤
             than grade 1, except for alopecia, neuropathy, and ANC, which should be ≥ 1250/mm3)
             induced by previous treatments. Any other investigational drugs should be discontinued
             2 weeks prior to the first dose of study medication.

          -  Prior therapy with an IGF-1R inhibitor
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ingrid Mayer, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt-Ingram Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Oncology Cool Springs</name>
      <address>
        <city>Franklin</city>
        <state>Tennessee</state>
        <zip>37067</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt One Hundre Oaks</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 17, 2010</study_first_submitted>
  <study_first_submitted_qc>September 17, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2010</study_first_posted>
  <results_first_submitted>June 7, 2012</results_first_submitted>
  <results_first_submitted_qc>August 10, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 11, 2012</results_first_posted>
  <last_update_submitted>August 10, 2012</last_update_submitted>
  <last_update_submitted_qc>August 10, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 11, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt-Ingram Cancer Center</investigator_affiliation>
    <investigator_full_name>Ingrid Mayer, MD</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine; Clinical Director, Breast Cancer Program; Medical Oncologist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
    <mesh_term>Goserelin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted from May 2010 and closed early one year later, May 2011.</recruitment_details>
      <pre_assignment_details>12 patients consented, one of which was determined to be ineligible.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>OSI-906 + Erlotinib + Letrozole + Goserelin</title>
          <description>OSI-906 in a pill form, by mouth, twice a day (12 hours a part)
Erlotinib in a pill form, by mouth, once a day
Letrozole in a pill form, by mouth, once a day
Goserelin, by injection once per month for women who are pre-menopausal</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Disease Progression</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>OSI-906 + Erlotinib + Letrozole + Goserelin</title>
          <description>OSI-906 in a pill form, by mouth, twice a day (12 hours a part)
Erlotinib in a pill form, by mouth, once a day
Letrozole in a pill form, by mouth, once a day
Goserelin, by injection once per month for women who are pre-menopausal</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Anti-tumor Activity of OSI-906</title>
        <description>Time to progression measured in months from study entry to date of disease progression</description>
        <time_frame>From study entry to 6 months</time_frame>
        <population>Patients who received treatment and who were available for determination of disease progression. One patient withdrew after beginning of treatment and was not available for determination of the duration of disease progression.</population>
        <group_list>
          <group group_id="O1">
            <title>OSI-906 + Erlotinib + Letrozole + Goserelin</title>
            <description>OSI-906 in a pill form, by mouth, twice a day (12 hours a part)
Erlotinib in a pill form, by mouth, once a day
Letrozole in a pill form, by mouth, once a day
Goserelin, by injection once per month for women who are pre-menopausal</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-tumor Activity of OSI-906</title>
          <description>Time to progression measured in months from study entry to date of disease progression</description>
          <population>Patients who received treatment and who were available for determination of disease progression. One patient withdrew after beginning of treatment and was not available for determination of the duration of disease progression.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="0" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety Profile Based on Number of Patients With Each Worst-grade Toxicity</title>
        <description>According to National Cancer Institute Common Toxicity Criteria for Adverse Events with 1 = mild, 2 = moderate, 3 = severe, 4 = life threatening/disabling, and 5 = death.</description>
        <time_frame>Every 4 weeks up to 24 weeks</time_frame>
        <population>Patients who received treatment and experienced an adverse event.</population>
        <group_list>
          <group group_id="O1">
            <title>OSI-906 + Erlotinib + Letrozole + Goserelin</title>
            <description>OSI-906 in a pill form, by mouth, twice a day (12 hours a part)
Erlotinib in a pill form, by mouth, once a day
Letrozole in a pill form, by mouth, once a day
Goserelin, by injection once per month for women who are pre-menopausal</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Profile Based on Number of Patients With Each Worst-grade Toxicity</title>
          <description>According to National Cancer Institute Common Toxicity Criteria for Adverse Events with 1 = mild, 2 = moderate, 3 = severe, 4 = life threatening/disabling, and 5 = death.</description>
          <population>Patients who received treatment and experienced an adverse event.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Patients with worst grade toxicity of 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients with worst grade toxicity of 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients with worst grade toxicity of 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients with worst grade toxicity of 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients with worst grade toxicity of 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Tumor Response Per RECIST</title>
        <description>Per RECIST criteria v. 1.1: measurable lesions: complete response (CR) disappearance of target lesions, partial response (PR) &gt; 30% decrease in the sum of the longest diameter (LD) of target lesions, progressive disease (PD) &gt; 20% increase in the sum of the LD of target lesions or appearance of new lesions, stable disease (SD) neither sufficient decrease nor increase of the sum of smallest sum of the LD of target lesions</description>
        <time_frame>Every 12 weeks to tumor progression</time_frame>
        <population>Patients who were available for measurement of tumor response.</population>
        <group_list>
          <group group_id="O1">
            <title>OSI-906 + Erlotinib + Letrozole + Goserelin</title>
            <description>OSI-906 in a pill form, by mouth, twice a day (12 hours a part)
Erlotinib in a pill form, by mouth, once a day
Letrozole in a pill form, by mouth, once a day
Goserelin, by injection once per month for women who are pre-menopausal</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Tumor Response Per RECIST</title>
          <description>Per RECIST criteria v. 1.1: measurable lesions: complete response (CR) disappearance of target lesions, partial response (PR) &gt; 30% decrease in the sum of the longest diameter (LD) of target lesions, progressive disease (PD) &gt; 20% increase in the sum of the LD of target lesions or appearance of new lesions, stable disease (SD) neither sufficient decrease nor increase of the sum of smallest sum of the LD of target lesions</description>
          <population>Patients who were available for measurement of tumor response.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Correlative Studies</title>
        <description>Biomarkers associated with response to OSI-906 + Erlotinib + Letrozole + Goserelin</description>
        <time_frame>&lt; or = to 2 weeks before initiation of Phase II study treatment period</time_frame>
        <population>No correlative studies were performed because the study did not move to the Phase II portion</population>
        <group_list>
          <group group_id="O1">
            <title>OSI-906 + Erlotinib + Letrozole + Goserelin</title>
            <description>OSI-906 in a pill form, by mouth, twice a day (12 hours a part)
Erlotinib in a pill form, by mouth, once a day
Letrozole in a pill form, by mouth, once a day
Goserelin, by injection once per month for women who are pre-menopausal</description>
          </group>
        </group_list>
        <measure>
          <title>Correlative Studies</title>
          <description>Biomarkers associated with response to OSI-906 + Erlotinib + Letrozole + Goserelin</description>
          <population>No correlative studies were performed because the study did not move to the Phase II portion</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>OSI-906 + Erlotinib + Letrozole + Goserelin</title>
          <description>OSI-906 in a pill form, by mouth, twice a day (12 hours a part)
Erlotinib in a pill form, by mouth, once a day
Letrozole in a pill form, by mouth, once a day
Goserelin, by injection once per month for women who are pre-menopausal</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>anemia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>leukocytosis</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="11" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>leukocytosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>electrocardiagram QT interval prolonged</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>hypothyroidism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>dry eye</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>eye disorders</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>dry mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>mucositis oral</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>gastrointestinal disorders Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>flu-like symptoms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>general disorders and administrative site disorders-other</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>flu-like symptoms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>alanine aminotransferase increased</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>alkaline phosphatase increased</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>aspartate aminotransferase increased</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>creatinine increased</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>neutrophil count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>white blood cells decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>anorexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>hypercalcemia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>hyperglycemia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>hypocalcemia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>hypoglycemia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>hypokalemia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>hyponatremia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>pain-bone</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>depression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>bladder spasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>urinary incontinence</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>acute kidney injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>epistaxis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>upper respiratory infection</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>dry skin</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>rash acneiform</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>rash macro-papular</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>skin and subcutaneous tissue disorders Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>pruritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Ingrid Mayer</name_or_title>
      <organization>Vanderbilt-Ingram Cancer Center</organization>
      <phone>615-936-2033</phone>
      <email>ingrid.mayer@vanderbilt.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

